Schroder Investment Management Group Sells 14,537 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Schroder Investment Management Group decreased its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 6.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 229,316 shares of the company’s stock after selling 14,537 shares during the period. Schroder Investment Management Group’s holdings in IDEAYA Biosciences were worth $5,717,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of IDYA. Vanguard Group Inc. increased its holdings in IDEAYA Biosciences by 5.9% during the fourth quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company’s stock worth $130,507,000 after buying an additional 282,936 shares during the last quarter. State Street Corp increased its stake in shares of IDEAYA Biosciences by 15.4% during the 3rd quarter. State Street Corp now owns 3,317,936 shares of the company’s stock worth $105,112,000 after purchasing an additional 443,640 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of IDEAYA Biosciences by 9.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,945,455 shares of the company’s stock worth $61,645,000 after purchasing an additional 172,838 shares during the period. Pictet Asset Management Holding SA grew its holdings in IDEAYA Biosciences by 2.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,941,271 shares of the company’s stock valued at $49,891,000 after purchasing an additional 46,931 shares during the period. Finally, Candriam S.C.A. raised its stake in shares of IDEAYA Biosciences by 14.0% in the fourth quarter. Candriam S.C.A. now owns 1,071,825 shares of the company’s stock valued at $27,546,000 after buying an additional 131,385 shares during the period. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Price Performance

Shares of IDYA opened at $14.71 on Friday. IDEAYA Biosciences, Inc. has a 1-year low of $14.40 and a 1-year high of $44.42. The company has a market capitalization of $1.29 billion, a P/E ratio of -4.46 and a beta of 0.51. The firm’s 50 day simple moving average is $20.05 and its 200 day simple moving average is $25.19.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The firm had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $7.00 million. On average, equities analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Wedbush reissued an “outperform” rating and issued a $52.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Stephens reaffirmed an “overweight” rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a report on Friday, February 14th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $61.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $53.58.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.